79 search results for: mechanism of disease

Itch: Neuroimmune Axis in Chronic Pruritic Skin <b>Disease</b>s
Dermatology
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.

View more
European Academy <b>of</b> Dermatology and Venereology (EADV) 2023 | Berlin
Congress
11
October
2023
Congress
European Academy of Dermatology and Venereology (EADV) 2023 | Berlin

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

Demystifying CPUO: Diagnosis and the Role <b>of</b> Type 2 Inflammation
Dermatology
Demystifying CPUO: Diagnosis and the Role of Type 2 Inflammation
expert video

Join Dr. Brian Kim in discussing the diagnosis of CPUO and the role of type 2 inflammation in disease pathophysiology.

View more
TBD
Dermatology
Prurigo Nodularis (PN): Understanding Its Clinical Features, Complex Burden, and Underlying Mechanisms
Infographic

Explore the clinical features, complex burden, and underlying mechanisms of PN.

View more
The Role <b>of</b> Type 2 Inflammation in Multiple <b>Disease</b> Trajectories
Dermatology
The Role of Type 2 Inflammation in Multiple Disease Trajectories
Infographic

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

View more
ADVENT at ATS 2026
On Demand
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
COPD and Asthma: What's the Difference and Is There a Link?
interactivity

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

View more
thumbnail
Congress
17
May
2026
Congress
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

EAPS
On Demand
Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

Bullous Pemphigoid (BP): Exploring New Frontiers
Dermatology
Bullous Pemphigoid (BP): Exploring New Frontiers
expert video

Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.

View more
The Benefits <b>of</b> Early Intervention in Reducing the Burden <b>of</b> <b>Disease</b> in Children With Atopic Dermatitis
On Demand
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.